View Older Stories View More Recent Stories

Dec 13, 2021 02:45PM Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Dec 13, 2021 05:20AM Gilead's (GILD) Kite Announces Yescarta Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
Dec 11, 2021 10:00AM Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
Dec 11, 2021 09:00AM Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
Dec 11, 2021 08:30AM Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Dec 10, 2021 08:00AM Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Nov 29, 2021 08:30AM Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
Nov 23, 2021 08:31AM Gilead Sciences (GILD) Trodelvy Granted European Commission Marketing Authorization for Treatment of Metastatic TNBC in Second Line
Nov 23, 2021 08:30AM Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
Nov 19, 2021 08:01AM Gilead Sciences (GILD) Submits BLA to FDA for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
Nov 19, 2021 08:00AM Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
Nov 18, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Nov 18, 2021 07:03AM Gilead (GILD) Exercises Options to Three Arcus Biosciences (RCUS) Clinical-stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
Nov 11, 2021 05:38AM Gilead Sciences (GILD) and Everest Medicine Announces Phase 2b Study of Sacituzumab Govitecan Meets Primary Overall Response Rate Endpoint
Nov 10, 2021 07:00PM Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Respon
Nov 9, 2021 10:00AM Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
Nov 4, 2021 09:23AM Gilead Sciences (GILD) and Kite Interim Data from ANCHOR Study of KUR-502
Nov 4, 2021 09:23AM Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
Oct 29, 2021 07:31AM Gilead Sciences's (GILD) Biktarvy Demonstrate Consistent Efficacy Profile in Real-World Setting
Oct 29, 2021 07:30AM Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
Oct 28, 2021 04:10PM Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Tripl
Oct 26, 2021 06:47AM Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr
Oct 26, 2021 06:45AM Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul
Oct 21, 2021 07:37AM Gilead Sciences (GILD) Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
Oct 21, 2021 07:37AM Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
Oct 19, 2021 08:30AM Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Oct 18, 2021 07:31AM Gilead Sciences (GILD) Announces FDA Approval of Expanded Indication of Gilead’s Biktarvy for Treatment of HIV-1 in Pediatric Population
Oct 18, 2021 07:30AM U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
Oct 15, 2021 08:03AM Gilead Sciences (GILD) Announces Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
Oct 15, 2021 08:00AM Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
Oct 14, 2021 04:05PM Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
Oct 1, 2021 05:46PM U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Sep 30, 2021 04:50PM Gilead's (GILD) Kite Submits sBLA to FDA for Earlier Use of Yescarta in Large B-cell Lymphoma
Sep 30, 2021 04:50PM Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
Sep 27, 2021 04:35PM Gilead Sciences (GILD) Marks Fifth Approval for Trodelvy in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
Sep 27, 2021 04:35PM Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
Sep 22, 2021 09:02AM Gilead Sciences (GILD) Announces Veklury Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Sep 22, 2021 09:01AM Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Sep 20, 2021 08:30AM Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
Sep 16, 2021 07:01AM Gilead (GILD) Announces New Data Demonstrate Trodelvy Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
Sep 16, 2021 07:01AM Gilead's (GILD) Trodelvy Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Sep 16, 2021 07:00AM New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
Sep 16, 2021 07:00AM Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Sep 13, 2021 08:30AM Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy
Sep 1, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Aug 19, 2021 04:18PM Gilead Sciences (GILD) Announces EMA Validates MAA for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
Aug 19, 2021 04:15PM European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited T
Aug 5, 2021 08:34AM Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer (GILD)
View More Recent Stories View Older Stories